clinical trial · NCT07791043
A Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Compared With Placebo in Adult Participants With Alcohol-related Liver Disease (ALD)
Liver Diseases, AlcoholicEfimosfermin alfaPlacebo
brief summary
This is a dose-ranging study to evaluate safety of efimosfermin alfa and to establish proof-of-concept that efimosfermin alfa therapy provides benefit in participants with ALD.
started
Aug 31, 2026
primary completion
Aug 11, 2028
completion
Jan 14, 2030
last updated
Sep 30, 2026
official title
A Dose-finding, Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate the Efficacy and Safety of Treatment With Efimosfermin Alfa in Adult Participants With Alcohol-related Liver Disease (ALD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol